Back to Screener

LivaNova PLC Ordinary Shares (LIVN)

Price$65.01

Favorite Metrics

Price vs S&P 500 (26W)18.07%
Price vs S&P 500 (4W)-2.13%
Market Capitalization$3.56B
P/E Ratio (Annual)61.31x

All Metrics

P/CF (Annual)13.98x
Book Value / Share (Quarterly)$21.96
P/TBV (Annual)3.46x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)10.75%
Cash Flow / Share (Quarterly)$3.17
Price vs S&P 500 (YTD)3.22%
Gross Margin (TTM)68.04%
Net Profit Margin (TTM)-17.47%
EPS (TTM)$-4.47
10-Day Avg Trading Volume0.73M
EPS Excl Extra (TTM)$-4.47
Revenue Growth (5Y)8.24%
EPS (Annual)$-4.45
ROI (Annual)-15.38%
Gross Margin (Annual)67.71%
Net Profit Margin (5Y Avg)-6.49%
Cash / Share (Quarterly)$11.63
Revenue Growth QoQ (YoY)12.16%
P/E Normalized (Annual)61.31x
ROA (Last FY)-9.30%
Revenue Growth TTM (YoY)10.74%
EBITD / Share (TTM)$-2.50
ROE (5Y Avg)-6.34%
Operating Margin (TTM)14.09%
Cash Flow / Share (Annual)$3.17
P/B Ratio2.96x
P/B Ratio (Quarterly)2.80x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.37x
Net Interest Coverage (TTM)-2.97x
ROA (TTM)-9.48%
EPS Growth QoQ (YoY)-44.41%
EV / EBITDA (TTM)29.01x
EPS Incl Extra (Annual)$-4.45
Current Ratio (Annual)1.36x
Quick Ratio (Quarterly)1.05x
3-Month Avg Trading Volume0.74M
52-Week Price Return83.70%
EV / Free Cash Flow (Annual)19.02x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$17.75
P/S Ratio (Annual)2.56x
Asset Turnover (Annual)0.53x
52-Week High$71.92
Operating Margin (5Y Avg)0.51%
EPS Excl Extra (Annual)$-4.45
CapEx CAGR (5Y)18.27%
Tangible BV CAGR (5Y)7.63%
26-Week Price Return22.05%
Quick Ratio (Annual)1.05x
13-Week Price Return4.42%
Total Debt / Equity (Annual)0.31x
Current Ratio (Quarterly)1.36x
Enterprise Value$3,296.494
Revenue / Share Growth (5Y)5.77%
Asset Turnover (TTM)0.54x
Book Value / Share Growth (5Y)-0.75%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.87x
Pretax Margin (Annual)-15.91%
Cash / Share (Annual)$11.63
3-Month Return Std Dev30.70%
Gross Margin (5Y Avg)68.29%
Net Income / Employee (TTM)$-0
EBITDA Interim CAGR (5Y)93.64%
ROE (Last FY)-20.21%
Net Interest Coverage (Annual)-2.97x
EPS Basic Excl Extra (Annual)$-4.45
P/FCF (TTM)20.52x
Receivables Turnover (TTM)6.79x
EV / Free Cash Flow (TTM)19.02x
Total Debt / Equity (Quarterly)0.31x
EPS Incl Extra (TTM)$-4.47
Receivables Turnover (Annual)6.79x
ROI (TTM)-15.19%
P/S Ratio (TTM)2.56x
Pretax Margin (5Y Avg)-7.05%
Revenue / Share (Annual)$25.45
Tangible BV / Share (Annual)$17.75
Forward P/E15.44x
Price vs S&P 500 (52W)53.87%
Year-to-Date Return5.87%
5-Day Price Return2.79%
EPS Normalized (Annual)$-4.45
ROA (5Y Avg)-3.20%
Net Profit Margin (Annual)-17.47%
Month-to-Date Return2.49%
Cash Flow / Share (TTM)$0.98
EBITD / Share (Annual)$-2.50
Operating Margin (Annual)14.09%
LT Debt / Equity (Annual)0.29x
P/CF (TTM)13.98x
ROI (5Y Avg)-4.99%
LT Debt / Equity (Quarterly)0.29x
EPS Basic Excl Extra (TTM)$-4.47
P/TBV (Quarterly)3.46x
P/B Ratio (Annual)2.80x
Inventory Turnover (TTM)2.84x
Pretax Margin (TTM)-15.91%
Book Value / Share (Annual)$21.96
Price vs S&P 500 (13W)3.74%
Beta0.91x
P/FCF (Annual)20.52x
Revenue / Share (TTM)$25.42
ROE (TTM)-21.48%
52-Week Low$34.00

Analyst Recommendations

Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.12
4.12
4.12
4.12

Industry Peers — Electromedical Equipment(29)

SymbolP/S Ratio (TTM)Revenue Growth (5Y)Gross Margin (TTM)Operating Margin (TTM)Price
LIVNLivaNova PLC Ordinary Shares
2.56x8.24%68.04%14.09%$65.01
MDTMedtronic plc
3.13x3.01%65.16%17.00%$85.65
MASIMasimo Corporation
6.12x5.95%61.90%20.30%$178.29
TMDXTransMedics Group, Inc. Common Stock
6.58x88.21%59.92%17.93%$109.12
ITGRInteger Holdings Corporation
1.63x11.55%27.39%11.90%$88.37
AXGNAxogen, Inc. Common Stock
7.92x14.93%74.31%-3.49%$37.37
CNMDCONMED Corporation
0.88x9.77%54.59%7.46%$37.91
BLFSBioLife Solutions Inc.
10.59x14.87%64.56%-17.26%$20.85
INMDInMode Ltd. Ordinary Shares
2.45x12.45%78.54%23.05%$14.33
CBLLCeriBell, Inc. Common Stock
8.68x87.89%-65.57%$20.74
CVCapsoVision, Inc. Common Stock
21.95x52.92%-188.25%$5.40

About

LivaNova is a UK-based medical-device company specializing in cardiopulmonary and neuromodulation solutions. Its portfolio includes heart-lung machines and oxygenation equipment for cardiac and respiratory support, as well as neuromodulation devices for treatment-resistant epilepsy and depression. The company generates approximately 50% of revenue from the US market, 21% from Europe, and the remainder from other regions.